neboglamine
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Glutamate [NMDA] receptorPOSITIVE ALLOSTERIC MODULATOR
Glutamate [NMDA] receptor positive allosteric modulator
PAM of the glycin-site on GRIN1-subunits, binds to other allosteric site?
- Glutamate receptor ionotropic, NMDA 1 (GRIN1) ↗
- Glutamate receptor ionotropic, NMDA 2A (GRIN2A) ↗
- Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ↗
- Glutamate receptor ionotropic, NMDA 2D (GRIN2D) ↗
- Glutamate receptor ionotropic, NMDA 3B (GRIN3B) ↗
- Glutamate receptor ionotropic, NMDA 2C (GRIN2C) ↗
- Glutamate receptor ionotropic, NMDA 3A (GRIN3A) ↗
- Glutamate (NMDA) receptor subunit zeta 1
- Glutamate [NMDA] receptor subunit epsilon 1
- Glutamate [NMDA] receptor subunit epsilon 2
- Glutamate [NMDA] receptor subunit 3A
- Glutamate [NMDA] receptor subunit epsilon 4
- Glutamate [NMDA] receptor subunit epsilon 3
- Glutamate NMDA receptor; GRIN1/GRIN2B
- Glutamate NMDA receptor; GRIN1/GRIN2A
- Ionotropic glutamate receptor NMDA 1/2C
- Ionotropic glutamate receptor NMDA 1/2D
- Glutamate NMDA receptor; GRIN1/GRIN2A/GRIN2B
- Glutamate receptor ionotropic, NMDA 1/2C/3B
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1- Mol. weight
- 256.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1255840 ↗
Also known as
- 4-amino-5-((4,4-dimethylcyclohexyl)amino)-5-oxopentanoic acid
- cr2249
- cr 2249
- cr-2249
- cr-2249
- cr-2249
- neboglamine
- neboglamine
- neboglamine
- (s)-4-amino-5-((4,4-dimethylcyclohexyl)amino)-5-oxopentanoic acid
- (s)-4-amino-n-(4,4-dimethylcyclohexyl)glutaramic acid
- xy-2401
- xy-2401